Although additional research is needed to fully elucidate the cellular and molecular pathways associated with the neuroprotective consequences of HDAC6 inhibition, it is becoming increasingly apparent that modulating HDAC6 activity may offer a very promising avenue for the treatment of AD and associated tauopathies. This evidence concerns the gene HDAC6 and Alzheimer disease.